NASDAQ:FPRXFive Prime Therapeutics Stock Price, Forecast & News

Five Prime Therapeutics' stock was trading at $2.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, FPRX shares have increased by 85.3% and is now trading at $5.43. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Five Prime Therapeutics.

Five Prime Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Five Prime Therapeutics.

Five Prime Therapeutics Inc (NASDAQ:FPRX) issued its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.67) by $0.10. The biotechnology company earned $8.41 million during the quarter, compared to the consensus estimate of $6.60 million. Five Prime Therapeutics had a negative return on equity of 72.79% and a negative net margin of 679.63%. View Five Prime Therapeutics' earnings history.

6 brokers have issued 12 month price targets for Five Prime Therapeutics' shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Five Prime Therapeutics' share price to reach $8.33 in the next year. This suggests a possible upside of 53.5% from the stock's current price. View analysts' price targets for Five Prime Therapeutics.

Headlines about FPRX stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Five Prime Therapeutics earned a coverage optimism score of 1.4 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an impact on the company's share price in the next several days. View the latest news aboutFive Prime Therapeutics.

Five Prime Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 1,320,000 shares, a decline of 5.0% from the April 30th total of 1,390,000 shares. Based on an average daily trading volume, of 372,200 shares, the days-to-cover ratio is currently 3.5 days. Currently, 3.7% of the shares of the company are short sold. View Five Prime Therapeutics' Current Options Chain.

Some companies that are related to Five Prime Therapeutics include Collegium Pharmaceutical (COLL), Cara Therapeutics (CARA), Kura Oncology (KURA), Kadmon (KDMN), Molecular Templates (MTEM), ZIOPHARM Oncology (ZIOP), Eagle Pharmaceuticals (EGRX), Retrophin (RTRX), Kala Pharmaceuticals (KALA), Homology Medicines (FIXX), Nabriva Therapeutics (NBRV), Ardelyx (ARDX), Akero Therapeutics (AKRO), Assembly Biosciences (ASMB) and G1 Therapeutics (GTHX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Five Prime Therapeutics investors own include Nektar Therapeutics (NKTR), Clovis Oncology (CLVS), Sangamo Therapeutics (SGMO), TG Therapeutics (TGTX), Amarin (AMRN), Gilead Sciences (GILD), ImmunoGen (IMGN), Ionis Pharmaceuticals (IONS), Opko Health (OPK) and Anavex Life Sciences (AVXL).

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

Five Prime Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.98%), Wellington Management Group LLP (3.39%), State Street Corp (1.68%), Geode Capital Management LLC (1.47%), Acadian Asset Management LLC (1.16%) and Two Sigma Advisers LP (1.14%). Company insiders that own Five Prime Therapeutics stock include Andrew T Feldstein, Bvf Partners L P/Il, Franklin M Berger and Value Fund L P Biotechnology. View institutional ownership trends for Five Prime Therapeutics.

FPRX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Assenagon Asset Management S.A., AQR Capital Management LLC, UBS Group AG, Tudor Investment Corp Et Al, GSA Capital Partners LLP, Wellington Management Group LLP, and State Street Corp. View insider buying and selling activity for Five Prime Therapeutics.

FPRX stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Healthcare of Ontario Pension Plan Trust Fund, SG Americas Securities LLC, Two Sigma Advisers LP, Nuveen Asset Management LLC, Parametric Portfolio Associates LLC, Invesco Ltd., and Geode Capital Management LLC. Company insiders that have bought Five Prime Therapeutics stock in the last two years include Andrew T Feldstein, Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Five Prime Therapeutics.

Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FPRX stock can currently be purchased for approximately $5.43.

Five Prime Therapeutics has a market capitalization of $198.93 million and generates $14.87 million in revenue each year. The biotechnology company earns $-137,200,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Five Prime Therapeutics employs 209 workers across the globe.

The official website for Five Prime Therapeutics is www.fiveprime.com.

Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600 or via email at [email protected]